Study Details

Back to Search Results

A Study to Evaluate Enzalutamide after Abiraterone in Metastatic Castration-Resistant Prostate Cancer

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02116582

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-0410

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-002271-17

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 years - N/A

Sex

Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

May 2014 - Sep 2017

Masking

None (Open Label)

Enrollment number

215

A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate Enzalutamide after Abiraterone in Metastatic Castration-Resistant Prostate Cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site DE49013

Reutlingen, Germany, 72764

Site FR33015

Angers cedex 02, France, 49055

Site ES34007

Sevilla, Spain, 41013

Site DE49005

Nuertingen, Germany, 72622

Site DE49015

Bergisch Gladbach, Germany, 51427

Site GB44001

Sutton, United Kingdom, SM2 5PT

Site BE32006

Turnhout, Belgium, 2300

Site FR33003

Marseille CEDEX 9, France, 13273

Site BE32004

Gent, Belgium, 9000

Site FR33009

Caen Cedex 05, France, 14076

Site GB44002

Glasgow, United Kingdom, G12 0YN

Site DE49008

Hamburg, Germany, 22399

Site FR33006

Lille, France, 59037

Site FR33014

Le Mans, France, 72015

Site GB44010

Plymouth, United Kingdom, PL6 8DH

Site DE49001

Hamburg, Germany, 22081

Site DE49014

Berlin, Germany, 10247

Site FR33011

Paris, France, 75005

Site DE49011

Waldshut-Tiengen, Germany, 79761

Site FR33002

Nimes, France, 30029

Site DE49007

Hannover, Germany, 30625

Site ES34004

Santiago de Compostela, Spain, 15706

Site ES34001

Madrid, Spain, 28007

Site ES34006

Barcelona, Spain, 08025

Site FR33012

Villejiuf, France, 94805

Site DE49016

Duesseldorf, Germany, 40225

Site FR33001

Paris cedex 15, France, 75908

Site ES34009

Badalona, Spain, 8916

Site DE49003

Berlin, Germany, 12200

Site BE32002

Liege, Belgium, 4000

Site ES34003

Madrid, Spain, 28034

Site ES34010

Madrid, Spain, 28044

Site GB44007

London, United Kingdom, SE1 9RT

Site BE32007

Hasselt, Belgium, 3500

Site BE32003

Kortrijk, Belgium, 8500

Site DE49012

Munster, Germany, 48149

Site FR33008

Nantes Saint Herblain Cedex, France, 44805

Site FR33005

Suresnes, France, 92151

Site DE49002

Heidelberg, Germany, 69120

Site DE49010

Dresden, Germany, 01307

Site ES34005

Pamplona, Spain, 31008

Site DE49017

Duisburg, Germany, 47179

Site DE49004

Goettingen, Germany, 37075

Site GB44006

Withington, United Kingdom, M204BX

Site GB44004

Birmingham, United Kingdom, B15 2TT

Site GB44003

Northwood, Middlesex, United Kingdom, HA6 2RN

Site FR33013

Lyon Cedex 3, France, 69003

Site DE49006

Tubingen, Germany, 72076

Site FR33007

Rennes, France, 35042

Site FR33010

Creteil cedex, France, 94010

Site ES34011

Barcelona, Spain, 08003

Site GB44009

Brighton, United Kingdom, BN2 5BE

Site ES34002

Madrid, Spain, 28040

Site BE32001

Brussels, Belgium, 1200

Site ES34008

Barcelona, Spain, 08035

Site DE49009

Bonn, Germany, 53111

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo